{"id":"W3169357178","doi":"10.1200/jco.2021.39.15_suppl.4098","title":"The cost effectiveness of lenvatinib versus atezolizumab and bevacizumab or sorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in Canada.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Lenvatinib; Medicine; Sorafenib; Oncology; Atezolizumab; Bevacizumab; Internal medicine; Hepatocellular carcinoma; Clinical endpoint; Clinical trial; Cancer; Nivolumab; Chemotherapy; Immunotherapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003863197,0.0009491086,0.001518221,0.001274547,0.0008101079,0.001629521,0.001733952,0.0008294596,0.002868425],"category_scores_gemma":[0.01111465,0.000619823,0.004701701,0.002341957,0.0007534246,0.0006524713,0.001286361,0.001556995,0.0001240532],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.08911584,"about_ca_system_score_gemma":0.04717875,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9268113,"about_ca_topic_score_gemma":0.9337615,"domain_scores_codex":[0.9971793,0.00134038,0.0001512594,0.0002104929,0.0004868888,0.0006317084],"domain_scores_gemma":[0.9963604,0.001550763,0.0007219771,0.00009189568,0.0006618389,0.0006131005],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"not_applicable","study_design_scores_codex":[0.07868911,0.001746823,0.2884874,0.009115255,0.03594738,0.001506193,0.0007818247,0.4313001,0.001351724,0.01170191,0.02011693,0.1192554],"study_design_scores_gemma":[0.02279749,0.009333381,0.4618646,0.003862358,0.04367089,0.001328057,0.002706155,0.4271757,0.001885561,0.007842948,0.01704772,0.0004852947],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9365692,0.0268078,0.002053925,0.005495511,0.0001519548,0.001352629,0.02023189,0.00006444617,0.007272645],"genre_scores_gemma":[0.9928874,0.002460672,0.0008765997,0.0003417706,0.00002353719,0.0001487649,0.002525955,0.000008883642,0.0007264288],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08911584,"threshold_uncertainty_score":0.6465837,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09492213808112498,"score_gpt":0.3345104232062748,"score_spread":0.2395882851251498,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}